Evidence map›Paper›PMID 32031616›Full record

ArticleInflammatory bowel diseases2020

Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine.

Anna Niechcial, Matthias Butter, Salomon Manz, Nicole Obialo, Katharina Bäbler, Lisa van der Lely, Silvia Lang, Claudia Gottier, Declan F McCole, Michael Scharl and 1 more

Open access · greenAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Modulation ofInternational journal of molecular sciences · 2021
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Anna NiechcialDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Matthias ButterDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Salomon ManzDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Nicole ObialoDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Katharina BäblerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Lisa van der LelyDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Silvia LangDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Claudia GottierDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Declan F McColeZurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
Michael ScharlDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Marianne R SpalingerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
University Hospital of Zurich · CHUniversity of Zurich · CHUniversity of California, Riverside · US

Funding

A NOVEL ROLE FOR PTPN2 IN INTESTINAL EPITHELIAL BARRIER REGULATIONR01DK091281 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Declan McCole · 2012 to 2026
$5.5M
NIDDK NIH HHS R01 DK091281
6 · The paper itself

Abstract

backgroundThe single nucleotide polymorphism (SNP) rs1893217 within the gene locus encoding PTPN2 represents a risk factor for inflammatory bowel disease (IBD). Our previous work demonstrated reduced PTPN2 activity and subsequently increased inflammatory signaling upon presence of SNP rs1893217. The naturally occurring polyamine spermidine reduces pro-inflammatory signaling via induction of PTPN2 activity; however, the effect of SNP rs1893217 on the anti-inflammatory potential of spermidine is still unknown. Here, we investigated how presence of SNP rs1893217 affects treatment efficacy of spermidine and whether it might serve as a potential biomarker for spermidine treatment.

methodsHuman T84 (wild-type [WT] for PTPN2 SNP rs1893217) and HT29 (heterozygous for PTPN2 SNP rs1893217) intestinal epithelial cells (IECs) were treated with several polyamines from the putrescine-spermidine pathway. T84 and HT29 IECs, THP-1 monocytes (WT and transfected with a lentiviral vector expressing PTPN2 SNP rs1893217) and genotyped, patient-derived peripheral blood mononuclear cells were challenged with IFN-γ and/or spermidine.

resultsAmong the analyzed polyamines, spermidine was the most efficient activator of PTPN2 phosphatase activity, regardless of the PTPN2 genotype. Spermidine suppressed IFN-γ-induced STAT1 and STAT3 phosphorylation, along with decreased mRNA expression of ICAM-1, NOD2, and IFNG in IECs and monocytes. Of note, these effects were clearly more pronounced when the disease-associated PTPN2 C-variant in SNP rs1893217 was present.

conclusionsOur data demonstrate that spermidine is the most potent polyamine in the putrescine-spermine axis for inducing PTPN2 enzymatic activity. The anti-inflammatory effect of spermidine is potentiated in the presence of SNP rs1893217, and this SNP might thus be a useful biomarker for possible spermidine-treatment in IBD patients.

Indexed as

Anti-Inflammatory AgentsCase-Control StudiesCell LineEpithelial CellsGenotypeHumansInflammatory Bowel DiseasesInterferon-gammaIntestinal MucosaLeukocytes, MononuclearPhosphorylationPolymorphism, Single NucleotideProtein Tyrosine Phosphatase, Non-Receptor Type 2Signal TransductionSpermidineAnti-Inflammatory AgentsInterferon-gammaProtein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, humanSpermidine

Identifiers

PMID32031616
PMCPMC7931847
OpenAlexW3004861822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.